Publications (147) Publications de Emilio José Sanz Álvarez

filter_list

2025

  1. Barriers and solutions for the European prescribing exam: a qualitative world café study

    European Journal of Clinical Pharmacology, Vol. 81, Núm. 10, pp. 1451-1459

  2. Clozapine pharmacovigilance in Croatia: Underreporting of specific adverse drug reactions and excellent reporting of suicide attempts: Clozapine Croatia suicide

    Psychiatry Research, Vol. 347

  3. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature

    Expert Opinion on Drug Safety

  4. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data

    European Child and Adolescent Psychiatry, Vol. 34, Núm. 7, pp. 2083-2091

  5. Fatal Outcomes in Use of Clozapine: A VigiBase Study of 6402 Women and 11,222 Men

    Journal of clinical psychopharmacology, Vol. 45, Núm. 6, pp. 547-553

  6. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I A Review of the Pharmacokinetic Literature and Proposed Changes

    Journal of Clinical Psychopharmacology, Vol. 45, Núm. 3, pp. 179-196

  7. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A review of fatal outcomes in US Pharmacovigilance data and proposed changes

    Journal of Clinical Psychopharmacology

  8. The Feasibility and Quality of the European Prescribing Exam: An International Multicenter Pilot Study Among 3109 Medical Students From 16 Medical Schools

    Clinical Pharmacology and Therapeutics

  9. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force

    European Psychiatry, Vol. 68, Núm. 1

2024

  1. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)

    Schizophrenia Research, Vol. 268, pp. 165-174

  2. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 53-59

  3. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 60-65

  4. Beyond lectures and practical courses: Teaching pharmacology using imaginative pedagogical tools

    Pharmacological Research, Vol. 202

  5. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature

    Expert Opinion on Drug Safety

  6. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database

    Schizophrenia Research, Vol. 268, pp. 118-130

  7. DIPEx TDAH: Recurso para comprender las vivencias y necesidades de las personas diagnosticadas de TDAH y su entorno en España

    Educar para la felicidad (Dykinson), pp. 1993-2001

  8. Enhancing therapeutic reasoning: key insights and recommendations for education in prescribing

    BMC Medical Education, Vol. 24, Núm. 1

  9. Investigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 20, Núm. 8, pp. 857-871

  10. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety

    Patient Preference and Adherence , Vol. 18, pp. 2261-2280

  11. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK

    Schizophrenia Research, Vol. 268, pp. 175-188